<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550209</url>
  </required_header>
  <id_info>
    <org_study_id>IRB17-00517</org_study_id>
    <secondary_id>R61AT009632</secondary_id>
    <nct_id>NCT03550209</nct_id>
  </id_info>
  <brief_title>Fatty Acid Supplementation in Children With ASD</brief_title>
  <acronym>Omega Heroes</acronym>
  <official_title>Fatty Acid Supplements Alter Biological Signatures in Children With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarah Keim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how fatty acid supplementation alters biological
      signatures in children with ASD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with Autism Spectrum Disorder (ASD) suffer from both mental and physical symptoms
      that affect their quality of life and severely disrupt family well-being. Fatty acid
      supplements are natural products with anti-inflammatory properties often used for treatment
      of ASD symptoms, but their efficacy remains unproven. The objective of the proposed protocol
      is to quantify the impact of Omega 3-6 on pre-specified biological signatures. The hypotheses
      were formulated based on data from the investigators previous studies and other published
      data which suggest that the inflammatory markers, IL-1β, IL-2, and IFNγ are consistently
      elevated in children with ASD and decreases in these markers correlate with ASD symptom
      improvement. The investigators long-term goal is to identify effective treatments for ASD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Group differences in bioavailability; each fatty acid as a percent of total erythrocyte fatty acids at the end of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Average number of adverse events per treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological Signatures</measure>
    <time_frame>Baseline to 90 days post-randomization</time_frame>
    <description>Changes in the biological signatures (IL-1β, IL-2, IFNγ) from baseline to the end of the trial.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>LCPUFA Oil Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canola Oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCPUFA Oil Supplement</intervention_name>
    <description>25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days</description>
    <arm_group_label>LCPUFA Oil Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Canola Oil Placebo</intervention_name>
    <description>Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days</description>
    <arm_group_label>Canola Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2-6 years old

          -  ASD diagnosis at Nationwide Children's Hospital within the prior 6 months

          -  ADOS-2 score in &quot;autism&quot; (severe) range

          -  English is primary language

        Exclusion Criteria:

          -  Fatty acid supplementation in the past 6 months

          -  Consumes fatty fish more than 3 times per week

          -  Still breastfeeding or formula feeding

          -  Quadriparesis

          -  Deafness

          -  Blindness

          -  Seizure disorder diagnosis

          -  Autoimmune disorder including Type 1 Diabetes, Fragile X, Rett, Angleman Syndromes,
             Tuberous Schlerosis

          -  Feeding problems precluding consumption of the supplement

          -  Ingredient allergy (canola, fish, or borage seed)

          -  Planned surgeries scheduled within the time frame of trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Keim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynette Rogers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sarah Keim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03550209/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

